L. Motley

T Cells Engineered with a Chimeric Antigen Receptor (CAR) Targeting CD19 (CTL019) Have Long Term Persistence and Induce Durable Remissions in Children with Relapsed, Refractory ALL

D. Teachey, S. Grupp, D. Porter, 2014 .

Risk-Adapted Preemptive Tocilizumab to Prevent Severe Cytokine Release Syndrome After CTL019 for Pediatric B-Cell Acute Lymphoblastic Leukemia: A Prospective Clinical Trial.

G. Wertheim, D. Teachey, S. Grupp, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Sustained remissions with CD19-specific chimeric antigen receptor (CAR)-modified T cells in children with relapsed/refractory ALL.

D. Teachey, S. Grupp, D. Porter, 2016 .

Risk-Adapted Preemptive Tocilizumab Decreases Severe Cytokine Release Syndrome (CRS) after CTL019 CD19-Targeted Chimeric Antigen Receptor (CAR) T-Cell Therapy for Pediatric B-Cell Acute Lymphoblastic Leukemia (B-ALL)

D. Teachey, S. Grupp, C. Callahan, 2020 .

Early administration of tocilizumab (Toci) for the prevention of grade 4 cytokine release syndrome (CRS) after CD19-directed CAR T-cell therapy (CTL019)

D. Teachey, S. Grupp, C. Callahan, 2019, Cytotherapy.

Durable Remissions in Children with Relapsed/Refractory ALL Treated with T Cells Engineered with a CD19-Targeted Chimeric Antigen Receptor (CTL019)

D. Teachey, S. Grupp, D. Porter, 2015 .

CAR T‐Cell Therapy Effects: Review of procedures and patient education

C. Callahan, Megan Harvey, Holly McConville, 2017 .

Effect of chimeric antigen receptor-modified T (CAR-T) cells on responses in children with non-CNS extramedullary relapse of CD19+ acute lymphoblastic leukemia (ALL).

D. Teachey, S. Grupp, B. Levine, 2017 .

Inpatient and Intensive Care Unit Resource Utilization after CD19-Targeted Chimeric Antigen Receptor T-Cell Therapy (CART19) for Pediatric Acute Lymphoblastic Leukemia (ALL)

Evanette K. Burrows, S. Grupp, M. Ramos, 2020 .